Bavarian Nordic has $340 mln orders for its mpox, smallpox vaccine in 2025
November 15, 2024
Danish biotech firm Bavarian Nordic projects a strong 2025, with $340 million in vaccine orders for mpox and smallpox. The company plays a critical role in addressing mpox outbreaks, which the WHO declared a global public health emergency again in August after clade Ib spread from the Democratic Republic of Congo. Bavarian Nordic’s vaccines target this viral infection, which causes flu-like symptoms and lesions. Alongside robust vaccine demand, the company anticipates growth in its Travel Health business and the launch of its chikungunya vaccine. Bavarian Nordic’s achievements highlight its vital contributions to global health and outbreak preparedness.
Bavarian Nordic, a leader in vaccine production for mpox and smallpox, anticipates a promising 2025 with an order book totaling $340 million, including deferred revenue. This follows the World Health Organization’s (WHO) August re-declaration of mpox as a global public health emergency. The clade Ib variant, originating in the Democratic Republic of Congo, has spread to neighboring countries, driving the urgent need for vaccinations.
Mpox, a viral infection causing flu-like symptoms and skin lesions, is generally mild but can be fatal in severe cases. Bavarian Nordic remains one of the few firms globally equipped to produce vaccines addressing this disease. Its vaccine is vital to controlling mpox outbreaks, particularly in regions most affected by the virus’s spread.
In addition to strong vaccine demand, Bavarian Nordic is poised for growth through its Travel Health division and the upcoming launch of its chikungunya vaccine in Europe and the U.S. While third-quarter sales saw a slight year-on-year decline, the company achieved profitability before interest and tax, reinforcing its financial stability. These achievements underline Bavarian Nordic’s capacity to adapt and innovate in response to emerging health threats.
As the global community grapples with recurrent infectious disease outbreaks, Bavarian Nordic’s continued success reflects the importance of having reliable vaccine manufacturers. With its focus on mpox, smallpox, and other critical public health concerns, the company is not only contributing to outbreak preparedness but also advancing solutions for neglected diseases like chikungunya. Bavarian Nordic’s role in addressing current and future health challenges solidifies its position as a cornerstone in global health security, ensuring that lifesaving vaccines are accessible when and where they are most needed.